NCT03166631: A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

NCT03166631
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: MBC patients are only eligible for Parts A & B of the study
Exclusions: Known presence of symptomatic central nervous system (CNS) metastases; Patients with known EGFR, ALK), ROS1 tumor aberrations, unless disease has progressed following available EGFR or ALK targeted therapy
https://ClinicalTrials.gov/show/NCT03166631

Comments are closed.

Up ↑